Background: We have been conducting a Japanese trial-ready cohort web study since 2019 as a web-based online registry to enroll individuals with preclinical Alzheimer's disease to facilitate trials on Alzheimer's disease prevention. The usability of a website might be an important factor in determining user participation and retention.
Objectives: We conducted a user questionnaire survey to analyze the usability of the Japanese trial-ready cohort website and user characteristics for future website improvement.
Design: This was a cross-sectional prospective observational study.
Setting: Online survey using Google Forms.
Participants: Among the Japanese trial-ready cohort web study participants, we enrolled those who provided consent to participate in the study and had completed one or more Cognitive Function Instrument tests before May 2, 2023. We sent an invitation e-mail, including the questionnaire web address, to eligible participants on July 21 and 22, 2023.
Measurements: We analyzed the questionnaire answers, including the system usability scale score and time of response (in 24 h). We also compared the respondents' characteristics with that of all the Japanese trial-ready cohort web study participants to identify features associated with an increased/decreased response rate to the questionnaire.
Results: Among the 10,112 Japanese trial-ready cohort web study participants that we sent invitation e-mails, we received 1,574 eligible responses (15.6%) within three weeks of the response acceptance period. The mean system usability scale score was 67.6, and no difference in system usability scale scores was observed in terms of age or sex. Approximately half of the respondents of the Japanese trial-ready cohort web study heard about it online, whereas one-fourth heard about it via newspapers. Contribution to drug development for dementia treatment was the most frequent motivation for participating in the Japanese trial-ready cohort web study (51.5%), followed by participation in the latest research (48.1%), concerns about self-memory (43.4%), and a family history of dementia (34.6%). Female respondents responded approximately 1.5 h later than male respondents. Lastly, those who had participated in the Japanese trial-ready cohort onsite study, were in their 70's, or had a larger number of Cognitive Function Instrument or Cogstate tests completion history were more likely to respond to the current online survey (relative risk of response > 1).
Conclusions: We conducted an online survey using Google Forms for participants in the Japanese trial-ready cohort web study to determine the usability. The results of this study might help to improve the user experience of the Japanese trial-ready cohort website itself, increase the web study registrants, maintain user retention, facilitate future online surveys, and serve as a reference for other web-based registries of presymptomatic disease status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14283/jpad.2024.48 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer's Disease in Japan.
Alzheimers Res Ther
October 2024
Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Article Synopsis
- The study investigates public and clinical specialists' perceptions regarding preparedness for administering disease-modifying treatments (DMT) for Alzheimer’s disease, focusing on the newly approved drug lecanemab.
- Conducted through online and mail surveys, it gathered responses from over 2,000 participants, highlighting significant differences in views about treatment eligibility and efficacy between general public respondents and clinical specialists.
- While both groups were generally supportive of prioritizing patients for treatment, the public expressed more restrictive views on who qualifies for DMT and appeared more optimistic about its effectiveness compared to specialists.
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
Alzheimers Res Ther
May 2024
Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
Background: Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early stage of Alzheimer's disease (AD). In this study, we elucidate the utility of combination of plasma amyloid-β (Aβ)-related biomarkers and tau phosphorylated at threonine 217 (p-tau217) to predict abnormal Aβ-positron emission tomography (PET) in the preclinical and prodromal AD.
Methods: We designed the cross-sectional study including two ethnically distinct cohorts, the Japanese trial-ready cohort for preclinica and prodromal AD (J-TRC) and the Swedish BioFINDER study.
Usability of a Web-Based Registry for Preclinical Alzheimer's Disease: Implications from a Cross-Sectional Online Survey.
J Prev Alzheimers Dis
May 2024
Kenichiro Sato and Takeshi Iwatsubo, Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, Japan, 113-8655, E-mail: Phone: +81-03-3815-5411.
Background: We have been conducting a Japanese trial-ready cohort web study since 2019 as a web-based online registry to enroll individuals with preclinical Alzheimer's disease to facilitate trials on Alzheimer's disease prevention. The usability of a website might be an important factor in determining user participation and retention.
Objectives: We conducted a user questionnaire survey to analyze the usability of the Japanese trial-ready cohort website and user characteristics for future website improvement.
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Alzheimers Dement
April 2023
Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, California, USA.
Article Synopsis
- Alzheimer's disease (AD) begins with a long asymptomatic stage characterized by the accumulation of amyloid beta (Aβ) before clinical symptoms arise; the AHEAD 3-45 Study tests if the drug lecanemab can intervene in this stage to slow decline.
- Launched in July 2020, the study includes two trials, A3 and A45, targeting cognitively unimpaired individuals aged 55-80, with different dosing based on their Aβ levels noted in PET scans.
- The study employs innovative recruitment methods to enrich the sample for those with elevated brain amyloid, using various registries and advanced plasma screening techniques to identify suitable participants.
Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study.
J Med Internet Res
July 2021
Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Background: Web-based screening may be suitable for identifying individuals with presymptomatic latent diseases for recruitment to clinical studies, as such people do not often visit hospitals in the presymptomatic stage. The promotion of such online screening studies is critical to their success, although it remains uncertain how the effectiveness of such promotion can differ, depending on the different promotion methods, domains of interest, or countries of implementation.
Objective: The Japanese Trial-Ready Cohort (J-TRC) web study is our ongoing online screening registry to identify individuals with presymptomatic Alzheimer disease (AD), aimed at facilitating the clinical trials for AD prevention.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!